IDEAYA's Darovasertib Combo Meets Primary Endpoint in Melanoma Trial, Targets H2 2026 NDA
Summary
IDEAYA Biosciences announced positive topline results from its Phase 2/3 registrational trial for darovasertib in metastatic uveal melanoma, meeting the primary endpoint of progression-free survival and showing strong overall response rates, with an NDA submission targeted for H2 2026.
Key Events
-
Positive Phase 2/3 Trial Results
The darovasertib combination met the primary endpoint of statistically significant improvement in median progression-free survival (PFS) in first-line metastatic uveal melanoma.
-
Strong Efficacy Data
Patients treated with the combination reduced their risk of disease progression by 58% (HR 0.42), achieving a median PFS of 6.9 months versus 3.1 months for the control arm. The overall response rate (ORR) was 37.1% compared to 5.8% in the control arm, with 5 complete responses observed.
-
Favorable Safety Profile
The darovasertib combination was generally well-tolerated with a manageable safety profile consistent with prior reported results.
-
Targeted NDA Submission
Based on these data, IDEAYA plans to submit a New Drug Application (NDA) to the U.S. FDA in the second half of 2026.
Analysis
This 8-K reports highly positive topline results from the OptimUM-02 Phase 2/3 registrational trial for darovasertib in combination with crizotinib for metastatic uveal melanoma. The trial successfully met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival and a substantial increase in overall response rates, including complete responses. This strong clinical data significantly de-risks the program and provides a clear path to market, with the company targeting an NDA submission in the second half of 2026. The positive news comes as the stock is already trading above its 52-week high, indicating strong investor confidence which these results are likely to reinforce.
At the time of this filing, IDYA was trading at $42.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $13.45 to $39.28. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.